Articles by Izzah Nawaz
Talquetamab remains effective in tough-to-treat myeloma—even when patients develop immune responses.
Mosunetuzumab’s mechanism of action involves connecting B-cells with T-cells for elimination by the immune system.
Elranatamab shows durable responses and manageable safety in heavily pretreated US patients with myeloma.
Blood clot risk tools may fall short for myeloma patients—study shows aspirin alone might not be enough.
Belantamab may return for RRMM after DREAMM trials show benefit, despite ongoing concerns about eye toxicity.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.